Feng Chi BiotechROCO:6744 +2.70%82 EBITDA Margin % is 14.76% as of Dec. 2025, which is 21% below its 10-year median of 18.61. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$20.86 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, Feng Chi Biotech ranks better than 79.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Feng Chi Biotech's EBITDA for the
six
months ended in Dec. 2025 was NT$12.0 Mil. Feng Chi Biotech's Revenue for the
six
months ended in Dec. 2025 was NT$81.3 Mil. Therefore, Feng Chi Biotech's EBITDA margin for the quarter that ended in Dec. 2025 was 14.76%.
Feng Chi Biotech (ROCO:6744) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Feng Chi Biotech EBITDA Margin % Related Terms
Feng Chi Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6744 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Feng Chi Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech (ROCO:6744) has a EBITDA Margin % of 14.76% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Feng Chi Biotech and its competitors. This is 21% below median its historical median of 18.61. Over the past decade, Feng Chi Biotech's EBITDA Margin % has ranged from 13.35 to 22.29. According to the industry distribution chart, Feng Chi Biotech ranks #191 out of 943 companies in the Biotechnology industry, placing it in the top 20.3%.
Is Feng Chi Biotech's EBITDA Margin % too high?
Feng Chi Biotech's current EBITDA Margin % of 14.76% is 21% below median its 10-year median of 18.61. Over the past 10 years, this metric has ranged from a low of 13.35 to a high of 22.29. Based on the distribution chart, Feng Chi Biotech ranks #191 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #191 out of 943 companies for EBITDA Margin %. This places Feng Chi Biotech in the top 20% of its industry — outperforming the majority of peers. Historically, Feng Chi Biotech's own EBITDA Margin % has ranged from 13.35 to 22.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current EBITDA Margin % is 14.76%, which is 21% below median its own 10-year median of 18.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.86, compared to a current price of NT$15.20 — trading 27.1% below its estimated fair value. The current EBITDA Margin % is 14.76%, which is 21% below median its 10-year median of 18.61. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current EBITDA Margin % is 14.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$15.20 is trading 27.1% below its estimated GF Value™ of NT$20.86.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
EBITDA Margin %: 14.76% (21% below median its 10-year median of 18.61)
GF Value™: NT$20.86 vs. price of NT$15.20 (27.1% below fair value)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score
Get the complete analysis for ROCO:6744
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
